Management of hepatocellular carcinoma

By Jordi Bruix1 , 2, M. Sherman. Hepatology, 2005

3,455 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/e85f91d0ab3d1a467f8ae732aae03c919c59bffc

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. J. Llovet
2. Jordi Bruix1 , 2
3. Yujin Hoshida
4. Alejandro Forner1 , 2
5. Sebastian M. B. Nijman
6. S. Friedman
7. Y. Saiman
8. J. Puche

In Hepatology

1. J. Llovet
2. Jordi Bruix1 , 2
3. Alejandro Forner1 , 2
4. Yujin Hoshida
5. S. Friedman
6. A. Villanueva
7. Riccardo Lencioni
8. M. Sherman

Citations in the corpus

• Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. (2007, methodology): “Following the EASL [12] and AASLD [8] guidelines the rate of objective responses increased to 66.”
• Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular Carcinoma (2009, background): “We were careful to analyze the two major patterns of HCC recurrence: early recurrence, which is related to residual dissemination of primary tumor cells within the liver, and late recurrence, which is attributable to new primary tumors arising in a hypercarcinogenic state of a cirrhotic liver (17, 1”
• Sorafenib in advanced hepatocellular carcinoma. (2008, neutral): “North America 27 (9) 29 (10) Central and South America 9 ( 3 ) 11 (4)”